EUVIMEDEUVIMED entdecken
Klinische StudieVergleichsstudieOpen Access

The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA—A secondary analysis

Marina Guirguis Hanna iD, Megan Bradley, Halina Zyczynski, Li Wang, Lauren Giugale

Neurourology and Urodynamics · 2023

DOI: 10.1002/nau.25191 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Neurourology and Urodynamics, 2023. Verfasst von Marina Guirguis Hanna und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urogynecology, Department of Obstetrics and Gynecology, Magee-Womens Hospital of UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania…. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Urinary Bladder, Overactive, Urinary Incontinence, Urinary Tract Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare treatment response in women who did and did not develop a urinary tract infection (UTI) within 14 days after intravesical onabotulinumtoxinA injections for treatment of refractory urgency urinary incontinence (UUI).

Methods

This is a secondary analysis of women who received Onabotulinumtoxin A in the Refractory Overactive Bladder: Sacral Neuromodulation vs Botulinum Toxin Assessment (ROSETTA) Trial. Participants were grouped by presence or absence of UTI within 14 days of injection. UTI was defined as symptomatic with positive urine culture per the primary ROSETTA protocol. Our primary outcome was change from baseline in mean number of UUI episodes based on monthly 3‐day bladder diaries averaged over 6 months. We performed t tests and chi‐square/Fisher's exact for continuous and categorical variables. A p value of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AUrinary Bladder, OveractiveUrinary IncontinenceUrinary Tract InfectionsFemaleHumansAdministration, IntravesicalTreatment OutcomeUrinary Incontinence, Urge

Stichwörter der Autor:innen

Botoxonabotulinumtoxin Aoveractive bladderurgency urinary incontinenceurinary tract infection

Substanzen

Botulinum Toxins, Type A

Autor:innen und Institutionen

  • Division of Urogynecology, Department of Obstetrics and Gynecology, Magee-Womens Hospital of UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Marina Guirguis Hanna

Förderung

  • NCATS NIH HHS

Zitieren

APA

Guirguis Hanna, M., Bradley, M., Zyczynski, H., Wang, L., & Giugale, L. (2023). The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA—A secondary analysis. Neurourology and Urodynamics. https://doi.org/10.1002/nau.25191

Vancouver

Guirguis Hanna M, Bradley M, Zyczynski H, Wang L, Giugale L. The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA—A secondary analysis. Neurourology and Urodynamics. 2023. doi:10.1002/nau.25191

BibTeX
@article{GuirguisHanna2023,
  author = {Guirguis Hanna, Marina and Bradley, Megan and Zyczynski, Halina and Wang, Li and Giugale, Lauren},
  title = {The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA—A secondary analysis},
  journal = {Neurourology and Urodynamics},
  year = {2023},
  doi = {10.1002/nau.25191}
}
Kostenlos starten →